Sertraline

證據等級: L5

預測適應症: 8 個

Sertraline: From Major Depressive Disorder to Agoraphobia

One-Sentence Summary

Sertraline (DrugBank DB01104) is a widely used SSRI antidepressant. Among the eight new indications TxGNN predicted for it, six are personality-disorder diagnoses that tie for the top score (99.93%) but are flagged in this same evidence pack as likely artifacts of dense "psychiatric disorder" clustering in the knowledge graph, with sparse or unrelated literature support. Agoraphobia, ranked lower numerically (score 99.54%), is by far the best-evidenced candidate — supported by 4 clinical trials (including a completed Phase 4 RCT, N=321) and 19 publications, including two network meta-analyses — and is therefore the focus of this report.

Quick Overview

Item	Content
Original Indication	Not specified in the regulatory data pack (no licenses on file). Sertraline is a well-established SSRI, generally indicated for major depressive disorder and anxiety-spectrum conditions including panic disorder.
Predicted New Indication	Agoraphobia
TxGNN Prediction Score	99.54% (rank 4295 of model output)
Evidence Level	L1
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Note on indication selection: The nominal rank-1 prediction (histrionic personality disorder, score 99.93%) and four other personality-disorder predictions tied at the same score are scored L4–L5 / Hold in this evidence pack — their supporting literature (e.g., MMPI-2 subscales, binge-eating disorder, lupus erythematosus) does not actually address those diagnoses. Agoraphobia is the only candidate in this pack that reaches L1 evidence and an active "Proceed" recommendation, so it is used as the primary subject of this report.

Why is This Prediction Reasonable?

Detailed drug-specific mechanism-of-action data was not available in this evidence pack (marked as a High-severity data gap, DG002, pending DrugBank API lookup). Based on general pharmacological knowledge, sertraline is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin availability, which is believed to dampen autonomic hyperarousal and anticipatory anxiety.

Panic disorder and agoraphobia are clinically intertwined — agoraphobia frequently develops as a secondary complication of recurrent, unpredictable panic attacks, and the two are diagnosed and treated together in most clinical trial designs (e.g., "panic disorder with or without agoraphobia" is the standard trial inclusion criterion seen throughout the evidence below). Sertraline is already an established, guideline-recommended treatment for panic disorder in multiple jurisdictions, so its mechanistic and clinical rationale extends naturally to agoraphobia as a shared-pathophysiology indication rather than an unrelated new disease area.

By contrast, the personality-disorder predictions that nominally scored higher lack this kind of mechanistic bridge: their evidence, per the pack's own rationale annotations, mostly concerns depression comorbidity, treatment-resistance augmentation, or incidental case reports — not treatment of the personality disorder itself.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00677352	Phase 4	Completed	321	Randomized, double-blind, multicenter comparison of sertraline vs. paroxetine in panic disorder; direct head-to-head efficacy/safety RCT
NCT00182533	Phase 4	Terminated	170	Sertraline in generalized social phobia with comorbidity; evaluated safety/efficacy in patients with co-occurring anxiety conditions, but stopped early
NCT05210153	N/A	Unknown	148	Utility of plasma drug-level monitoring and CYP2C19 genotyping for sertraline dose personalization (pharmacokinetic, not efficacy, evidence)
NCT05930912	N/A	Unknown	1	Psychoanalytic treatment context in ASD with comorbid anxiety; n=1, weak relevance to sertraline pharmacotherapy

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35045991	2022	Network Meta-analysis	BMJ	Compares SSRIs and other drug classes for remission rates and adverse-event risk in panic disorder with/without agoraphobia
38014714	2023	Network Meta-analysis (Cochrane)	Cochrane Database Syst Rev	Systematic comparison of pharmacological treatments for panic disorder in adults
16053461	2005	RCT	Bosnian J Basic Med Sci	Placebo-controlled comparison of sertraline vs. alprazolam for panic disorder with/without agoraphobia
16505130	2006	RCT	Am J Geriatric Psychiatry	CBT vs. sertraline for anxiety disorders (including agoraphobia) in older adults
12191627	2002	RCT	J Psychiatric Research	Pooled data from 4 sertraline/placebo trials; early improvement predicts remission in panic disorder
11206597	2000	RCT	J Clin Psychiatry	Sertraline response in panic disorder patients at risk for poor outcome, including those with agoraphobia
9734541	1998	RCT	Am J Psychiatry	Double-blind multicenter trial establishing efficacy and safety of sertraline in panic disorder
36573969	2022	Review	JAMA	General review of anxiety disorders, including panic disorder/agoraphobia treatment landscape
11110016	2000	Review	Int Clin Psychopharmacol	Summarizes comparator-controlled SSRI trials (including sertraline) for panic disorder and agoraphobia
37676054	2023	Systematic Review	Expert Rev Neurother	Pharmacological management of panic disorder in older patients

New Zealand Market Information

Currently no marketing authorizations on file for sertraline in New Zealand (0 licenses; market_status: 未上市 — not marketed).

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all marked as data gaps in this evidence pack; DG001 — missing Medsafe/TFDA package insert warnings — is flagged as Blocking for safety review.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Sertraline's use in panic disorder with agoraphobia is backed by L1 evidence — a completed Phase 4 RCT plus two independent network meta-analyses — and a coherent shared-pathophysiology mechanism. However, the drug has zero regulatory authorizations and no package-insert safety data in this market, so it cannot move past S1 safety screening yet.

To proceed, the following is needed:

TFDA/Medsafe package insert (warnings, contraindications) — currently a Blocking data gap (DG001)
Confirmed mechanism-of-action data from DrugBank (DG002)
Local regulatory pathway assessment given current "not marketed" status (0 licenses)
Route-of-administration compatibility check (currently unassessed/pending in this pack)
Discard or deprioritize the six tied top-score personality-disorder predictions — their literature support does not substantiate a treatment effect and should not consume further review resources
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.